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Introduction: Cell-adhesion molecules play important roles involv-
ing the malignant phenotypes of human cancer cells. However, 
detailed characteristics of aberrant expression status of cell-adhesion 
molecules in malignant mesothelioma (MM) cells and their possible 
biological roles for MM malignancy remain poorly understood.
Methods: DNA microarray analysis was employed to identify aber-
rantly expressing genes using 20 MM cell lines. Activated leukocyte 
cell-adhesion molecule (ALCAM) expression in MM cell lines was 
analyzed with quantitative reverse transcription-polymerase chain 
reaction and Western blot analyses in 47 primary MM specimens 
with immunohistochemistry. ALCAM knockdown in MM cell lines 
was performed with lentivirus-mediated short hairpin RNA (shRNA) 
transduction. Purified soluble ALCAM (sALCAM) protein was used 
for in vitro experiments, whereas MM cell lines infected with the sAL-
CAM-expressing lentivirus were tested for tumorigenicity in vivo.
Results: ALCAM, a member of the immunoglobulin superfamily, 
was detected as one of the most highly upregulated genes among 103 
cell-adhesion molecules with microarray analysis. Elevated expres-
sion levels of ALCAM messenger RNA and protein were detected 
in all 20 cell lines. Positive staining of ALCAM was detected in 26 
of 47 MM specimens (55%) with immunohistochemistry. ALCAM 
knockdown with shRNA suppressed cell migration and invasion of 
MM cell lines. Purified sALCAM protein impaired the migration and 
invasion of MM cells in vitro, and the infection of sALCAM-ex-
pressing virus into MM cells significantly prolonged survival periods 
of MM-transplanted nude mice in vivo.
Conclusion: our study suggests that overexpression of ALCAM 
contributes to tumor progression in MM and that ALCAM might be 
a potential therapeutic target of MM.
Key Words: Activated leukocyte cell-adhesion molecule (ALCAM), 
Malignant mesothelioma, Migration, Invasion, Soluble isoform.
(J Thorac Oncol. 2012;7: 890–899)
Malignant mesothelioma (MM) is an aggressive tumor arising from mesothelial cells of the pleural or peri-
toneal cavity, and exposure to asbestos is considered to play 
a crucial role in tumor development.1–5 Despite advances in 
the chemotherapeutical modalities combining cisplatin and 
antifolate agent such as pemetrexed6 or the trials of radical 
multimodal therapy including neoadjuvant chemotherapy 
followed by extrapleural pneumonectomy and hemithoracic 
radiation,7–9 the prognosis of patients with MM remains very 
poor. New approaches to the treatment are needed to improve 
their outcome.
Aberrant expressions of cell-adhesion molecules in can-
cer cells play important roles in cell proliferation, migration, 
and metastasis.10,11 As for cell-adhesion molecules associated 
with MM, positivity of N-cadherin or CD141 and negativ-
ity of E-cadherin or CD15 have been proposed to be useful 
diagnostic findings for the epithelial type of MM.12 Recently, 
CD146 has been proposed as an immunocytochemical marker 
for differential diagnosis of MM from reactive mesothelium.13 
However, only a few reports have aimed to resolve the rela-
tionship between aberrant expression of cell-adhesion mol-
ecules and MM progression.14–16
Activated leukocyte cell-adhesion molecule (ALCAM/
CD166) is a type-I transmembrane protein and a member 
of the immunoglobulin superfamily.17,18 ALCAM comprises 
five extracellular immunoglobulin-like molecules (D1–D5), 
a transmembrane domain, and a short CooH-terminal cyto-
plasmic tail (Supplementary Figure 1A, Supplemental Digital 
Content 1, http://links.lww.com/JTo/A259).19 ALCAM was 
first identified on activated leukocytes as a ligand of CD6,20,21 
and ALCAM-CD6-mediated adhesion was shown to contribute 
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to T-cell activation or proliferation.22,23 Meanwhile, ALCAM 
was also demonstrated to mediate homophilic ALCAM-to-
ALCAM interaction,24,25 which was shown to be involved in 
physiological processes including angiogenesis,26 immune 
response,27 and cell migration during the neuronal develop-
ment.28 As for carcinogenesis, ALCAM has been reported to 
participate in the promotion of cell migration or invasion in 
vitro29,30 and the enhancement of tissue invasion and metas-
tases in vivo.31 In primary malignant tumors, overexpression 
of ALCAM has also been demonstrated to be pathologically 
correlated with aggressiveness in colorectal cancer,32 gastric 
cancer,33 and various types of cancers.34–39
Meanwhile, a soluble isoform of ALCAM (sALCAM) 
has also been identified as an alternative, shortened ALCAM 
transcript.26 This transcript contains only one of the five 
immunoglobulin domains, D1, which was shown to be the 
most important region for ligand binding (Supplementary 
Figure 1C, Supplemental Digital Content 1, http://links.lww.
com/JTo/A259).25 sALCAM was shown to block homophilic 
binding of ALCAM, and was considered to have a regulatory 
role in blocking endogenous ALCAM function.27 Moreover, 
sALCAM was also demonstrated to inhibit tumor progres-
sion; sALCAM treatment impaired melanoma cell migration 
in vitro and diminished metastatic properties in vivo.31
In this study, we found ALCAM to be one of the most 
upregulated genes among cell-adhesion molecule-encoding 
genes in MM cell lines and showed the overexpression of 
ALCAM in more than half of MM primary tumors. We showed 
that ALCAM knockdown by short hairpin RNA (shRNA) 
exerted inhibitory effects on cell migration and invasion of 
MM cells. Furthermore, we demonstrated that the sALCAM 
attenuated the malignant phenotypes of MM cells in vitro and 
that a xenographic murine model inoculated with MM cells that 
were infected with sALCAM-expressing lentivirus showed a 
prolonged survival. our results indicate that ALCAM has a 
significant role in MM cell progression and that ALCAM may 
well be a molecular target against MM cells.
MATERIALS AND METHODS
Cell Lines and Primary Specimens of MM
Fourteen Japanese MM cell lines, including ACC-
MESo-1, -4, Y-MESo-8D, -9, -12, -14, -21, -22, -25, -26B, 
-27, -28, -29, and -30, were established in our laboratory as 
reported previously and described elsewhere, and the cells at 
10 to 15 passages were used for assays.40 Four MM cell lines 
including NCI-H28, NCI-H2052, NCI-H2373, and MSTo-
211H, and one immortalized mesothelial cell line, MeT-5A, 
were purchased from the American Type Culture Collection 
(ATCC) (Rockville, MD), and cells at 3 to 5 passages were 
used. NCI-H290 and NCI-H2452 were the kind gift of Dr. 
Adi F. Gazdar. All MM cell lines were cultured in RPMI1640 
medium supplemented with 10% fetal calf serum and 1× 
antibiotic-antimycotic (Invitrogen, Carlsbad, CA) at 37°C in 
a humidified incubator with 5% Co
2
. MeT-5A was cultured 
according to ATCC instructions. Two primary cultures of nor-
mal mesothelial cells at 3 to 5 passages derived from ascites 
of patients with ovarian cancer, oV-M1, gastric cancer, GAS-
M1, were also used. Forty-seven primary specimens of MMs 
used included 35 pleura, 6 peritoneum, and 6 other sites of ori-
gins. Histological classification was 34 epithelial, 6 biphasic, 
5 spindle, 1 desmoplastic, and 1 lymphohistiocytoid. Among 
47 MMs, 28 were MM tissue samples obtained from patients 
at Aichi Cancer Center Hospital, Nagoya University Hospital, 
Japanese Red Cross Nagoya First Hospital, Toyota Kosei 
Hospital, and Kasugai Municipal Hospital according to the 
Institutional Review Board-approved protocol of each and the 
written informed consent from each patient. Fifteen primary 
MM samples were obtained as result of biopsy, 11 samples via 
extrapleural pneumonectomy and 2 samples were collected 
via pleurectomy/decortication. overall survival was measured 
from the date of surgery until death or the final date of the 
follow-up. The median length of follow-up for patients was 
12 months (range, 2–38 months). Normal lung samples were 
obtained from patients with lung cancer who had undergone 
curative pulmonary resection. The other 19 MM samples were 
from the human mesothelioma tissue array from US Biomax 
(Rockville, MD).
Antibodies
Mouse anti-ALCAM antibody (clone MoG/07 and 
SNCL-CD166) for Western blot and immunohistochemical 
analysis was purchased from Novocastra (Newcastle, U.K.). 
Mouse anti-ALCAM (clone 3A6, 559260) for immunofluores-
cence was purchased from BD Bioscience Discovery Labware 
(Bedford, MA) and mouse anti-b-actin (clone AC74) was from 
Sigma (St. Louis, Mo). Rabbit anti-b-catenin antibody (sc-
7199) was purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA), and mouse anti-V5 was from Invitrogen.
Construction of RNA Interference Vectors 
and Expression Vectors
Complementary short hairpin (sh) sequence was cloned 
into pLentiLox3.741 under control of a U6 promoter and trans-
fected into HEK293FT cells along with the vectors of VSVG, 
RSV-Rev, and pMDLg-pRPE, to generate lentiviruses that 
transcribe shRNA. Two sh oligonucleotides were designed 
for two different sequences within the ALCAM open reading 
frame (ALCAM-Sh1, 5-GAGGAATCTCCTTATATTA-3 and 
ALCAM-Sh2, 5-GGATAACATCACTCTTAAA-3). Control 
vectors, ALCAM-Scr1 (5-GTTTACCACGGAATATTAT-3) 
and ALCAM-Scr2 (5-GAAACCTTTTCAGCAATAA-3) 
were constructed using oligonucleotides with scrambled 
sequence for ALCAM-Sh1 and ALCAM-Sh2. The efficacy of 
each virus was tested by immunoblotting of whole cell lysates 
96 hours after infecting NCI-H290 cells at the multiplicity of 
infection of 10. The cDNA fragments of wild-type ALCAM 
or sALCAM were amplified by PCR using PrimeSTAR Max 
DNA polymerase (Takara Bio, otsu, Japan), and introduced 
into the pcDNA3.1 V5-His expression vector (Invitrogen), 
thereby fusing these cDNAs with the V5-His sequence. The 
sequences of all constructs were confirmed. To generate wild-
type ALCAM- or sALCAM-expressing lentiviral vectors, 
cDNA coding for ALCAM or sALCAM tagged with V5-His 
was amplified with PCR and cloned into the pLL3.7Lox 
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lentiviral vector with an infusion cloning system (Clontech, 
Mountain View, CA).
Purification of sALCAM
HEK293FT cells were infected with V5-His-tagged 
sALCAM-expressing or empty virus as a control. Ninety-six 
hours after infection, the media were exchanged to serum-
free medium and cells were incubated for 24 hours. The con-
ditioned media were collected and subjected to purification 
of sALCAM using the His-tagged protein purification kit 
(Qiagen K.K., Tokyo, Japan). Purified His-tagged proteins 
were dialysed to remove buffer-containing imidazole and 
sodium using Biotech Cellulose Ester membranes (Spectrum 
Laboratories, Rancho Dominguez, CA). Then, proteins were 
filtrated at a concentration of 20-fold using Amicon Ultra-0.5 
devices (Millipore, Bedford, MA).
Animals and Implantation Model
Female KSN/Slc nude mice (nu/nu) were obtained from 
Japan SLC (Hamamatsu, Japan) and maintained under specific 
pathogen-free conditions throughout this study. NCI-H290 
cells either infected with sALCAM-V5- or GFP-lentivirus 
were harvested using trypsin/EDTA, washed twice, and sus-
pended in phosphate-buffered saline. Six-week-old mice were 
injected with 1 × 106 cells in 100 μl of PBS into the right 
thoracic cavity. Survival was measured from the date of injec-
tion of MM cells until death. All experiments were performed 
in accordance with the guidelines established by the Aichi 
Cancer Center Committee on Animal Care and Use.
Additional materials and methods are described in 
Supplementary Material and Methods (Supplemental Digital 
Content 2, http://links.lww.com/JTo/A260).
RESULTS
ALCAM Expression in MM Cell Lines and 
Primary Tissues
To determine what types of cell-adhesion molecules 
are aberrantly expressed in MM cells, we performed microar-
ray analysis using 20 MM cell lines. Among 103 genes that 
encode cell-adhesion molecules from the array, we listed the 
top 10 genes that showed either up- or downregulation in MM 
cells (Supplementary Table 1, Supplemental Digital Content 
3, http://links.lww.com/JTo/A261). Because ALCAM was the 
second- highest scoring gene and has been reported to be asso-
ciated with other types of human malignancies, we focused on 
ALCAM for its roles in the pathogenesis of MM. To validate 
the microarray data, we next examined the expression sta-
tus of ALCAM with quantitative reverse transcription-poly-
merase chain reaction and Western blot analyses. Comparing 
with the expression level of ALCAM mRNA in an immortal-
ized mesothelial cell line, MeT-5A, which was arbitrarily set 
as 1.0, all 20 cell lines expressed more than 4.5-fold ALCAM 
mRNA, with 15 cell lines being more than 20-fold (Fig. 1A). 
Meanwhile, two primary cell cultures of normal mesothe-
lial cells, oV-M1, and GAS-M1, also showed relatively low 
expression of ALCAM. Western blot analysis also confirmed 
increased ALCAM protein in all 20 cell lines, which seemed 
to be consistent with mRNA expression levels (Fig. 1B). Each 
MM cell line expressed ALCAM of different sizes. The dif-
ferent sizes of ALCAM were thought to be not only because 
of different posttranslational modifications of the ALCAM 
protein such as glycosylation, but also because of splice vari-
ants (variant 1, 2, and 3) of the ALCAM gene, with the esti-
mated molecular weight of each being 65.1, 63.6, and 61.9 
kDa, respectively.19 We also performed immunocytochemical 
analysis using NCI-H290 cells and observed strong signals at 
cell-to-cell interaction regions (Fig. 1C). However, ALCAM 
signals in MeT-5A cells were undetectable (Fig. 1C).
To study whether ALCAM expression detected in MM 
cell lines reflects primary MMs, we investigated ALCAM 
expression in 47 MM specimens with immunohistochemical 
analysis. We detected 9 specimens (19%) for 3+, 17 (36%) 
for 2+, 14 (30%) for 1+, and 7 (15%) for 0 score, indicat-
ing that 26 of 47 specimens (55%) were positive (3+ or 2+) 
for ALCAM. As five specimens were the origins of cell lines, 
we compared them and found that four pairs of cell lines and 
primary tumors (Y-MESo-9/KD1048, Y-MESo-12/KD1050, 
Y-MESo-14/KD1053, and Y-MESo-21/KD1056) showed 
a well-concordant expression of ALCAM (Figs. 2A–D). 
Although the Y-MESo-26B cell line showed a high expression 
of ALCAM, its corresponding primary specimen, KD1062, 
showed faint staining (1+) of ALCAM (Fig. 2E). Meanwhile, 
normal pleural mesothelial cells also showed faint staining 
(1+) (Fig. 2F). We investigated the relationship between the 
ALCAM immunohistochemical staining status and clinico-
pathological characteristics of MMs. However, there was no 
significant relationship between ALCAM expression and the 
sites of origin or histological subtypes (Supplementary Table 
2, Supplemental Digital Content 4, http://links.lww.com/ 
JTo/A262). Survival data of 22 patients were also available 
from 28 of our patients. However, we did not detect a sig-
nificant association between the ALCAM expression and the 
patients’ survival (data not shown).
Inhibition of ALCAM-Suppressed Migration 
and Invasion of Mesothelioma Cells
As ALCAM is reportedly involved in the promotion of 
tumor cell migration and invasion in other types of human 
malignancies, we investigated whether or not inhibition of 
ALCAM suppresses malignant phenotypes of MM cells. We 
selected H290 and Y-MESo-27 as representative cell lines 
with high and moderate ALCAM protein expression, respec-
tively. We synthesized two ALCAM shRNA constructs and 
confirmed ALCAM-Sh1 suppressed ALCAM protein expres-
sion more efficiently than ALCAM-Sh2 in two mesothelioma 
cell lines (Fig. 3A). Using these ALCAM-Sh constructs, we 
found that ALCAM knockdown induced 30 to 50% inhibi-
tion of cell migration and invasion of both cell lines (Fig. 
3B). We further carried out colony formation assay and found 
that ALCAM knockdown also impaired anchorage-indepen-
dent cell growth (Fig. 3C). However, we did not detect the 
inhibitory effect on cell proliferation by ALCAM knockdown 
(Supplementary Figure 2, Supplemental Digital Content 5, 
http://links.lww.com/JTo/A263).
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FIGURE 1. Expression of ALCAM in MM cell lines. (A) Quantitative RT-PCR analysis of ALCAM in 20 MM cell lines, 1 immortal-
ized cell line, MeT-5A, and 2 primary normal mesothelial cultures, OV-M1 and GAS-M1. Relative expression of MeT-5A was 
arbitrarily set at 1.0, (B) Western blot analysis of ALCAM in 20 MM cell lines. Expression of b-actin was used as the control, 
(C) Immunocytochemical analysis. Strong, membranous signals of ALCAM were observed in NCI-H290 cells, but no signals in 
MeT-5A cells. b-catenin staining was used as the marker of the cell-to-cell interaction region. ALCAM, Activated leukocyte cell-
adhesion molecule; MM, malignant mesothelioma; RT-PCR, reverse transcription polymerase chain reaction.
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ALCAM Induces Enhancement of Migration and 
Anchorage-Independent Growth of Normal 
Mesothelial Cells
To determine whether ALCAM confers malignant phe-
notypes to normal mesothelial cells, we infected the wild-type 
ALCAM virus into MeT-5A cells (Fig. 4A). With immunocy-
tochemical analysis, we confirmed that ectopically expressed 
ALCAM was localized at the cell-to-cell interaction regions 
(Fig. 4B). We found that the transduction of ALCAM increased 
cell migration and anchorage-independent cell growth of 
MeT-5A cells (Fig. 4C). However, we could not observe the 
enhancement of cell invasion ability (data not shown). As 
expected, we did not detect promotion of MeT-5A cell prolif-
eration with enhanced ALCAM expression (Supplementary 
Figure 3, Supplemental Digital Content 6, http://links.lww.com/
JTo/A264); this suggested that ALCAM does not affect cell 
proliferation itself as seen in ALCAM-knockdown MM cells.
Regulatory Effect of sALCAM on ALCAM 
Function
To evaluate a possible inhibitory effect of the soluble 
form, sALCAM (Supplementary Figure 1C, Supplemental 
Digital Content 1, http://links.lww.com/JTo/A259), on MM 
cells we generated sALCAM expression virus with V5-epitope 
tag that was attached at the CooH-terminal, and infected 
HEK293FT cells with them to synthesize sALCAM protein. 
With Western blot analysis using anti-V5 antibody, sAL-
CAM was detected in the cell lysates and conditioned culture 
medium of HEK293FT/sALCAM-V5 cells (Fig. 5A). We then 
purified the His-tagged sALCAM protein from conditioned 
culture medium, and the purity was confirmed by silver stain-
ing (Fig. 5B). We added sALCAM in the culture medium of 
MM cell lines and found that sALCAM induced 20 to 40% 
inhibition of cell migration and invasion of MM cells (Fig. 
5C). We further demonstrated that purified sALCAM signifi-
cantly impaired anchorage-independent cell growth of MM 
cells (Fig. 5D). However, we did not observe any inhibitory 
effect of sALCAM on cell proliferation (Supplementary 
Figure 5, Supplemental Digital Content 1, http://links.lww.
com/JTo/A265).
Survival Benefit of sALCAM in MM Cell-Bearing 
Nude Mice
To assess the possible therapeutic effect of sALCAM in 
vivo, we infected NCI-H290 cells with sALCAM-expressing 
virus and injected them into the right thoracic cavity of nude 
mice. We found that nude mice inoculated with the MM cell 
line with sALCAM expression, NCI-H290/sALCAM-V5, 
exhibited significantly prolonged survival time, compared 
with the control, NCI-H290/GFP (Fig. 6). Autopsy using 
Western blot and immunohistochemical analyses served to 
confirm stable expression of sALCAM in the thoracic tumors 
(Supplementary Figure 5, Supplemental Digital Content 8, 
http://links.lww.com/JTo/A266).
DISCUSSION
In the present study, we found that ALCAM is one of 
the most highly upregulated genes among cell adhesion-re-
lated genes in MM cells and that ALCAM gives a malignant 
phenotype to MM cells. We showed elevated expression of 
FIGURE 2. Immunohistochemical analysis of ALCAM in primary MM specimens. ALCAM was positive in KD1048 (3+) (A), 
KD1050 (2+) (B), KD1053 (3+) (C), and KD1056 (3+) (D). These samples were the origins of Y-MESO-9 cell line (20.2 for rela-
tive ALCAM mRNA level), Y-MESO-12 (4.7), Y-MESO-14 (35.2), and Y-MESO-21 (51.6), respectively, as shown in Figure 1A. 
Although KD1062 showed faint staining (1+) (E), its corresponding cell line, Y-MESO-26B, showed high ALCAM expression 
(30.4). Normal pleural mesothelial cells (arrows) (F) showed faint staining (1+) of ALCAM. ALCAM, Activated leukocyte cell-
adhesion molecule; MM, malignant mesothelioma; mRNA, messengerRNA.
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FIGURE 3. Lentiviral shRNA-mediated ALCAM knockdown in two MM cell lines, NCI-H290 and Y-MESO-27. (A) Western blot 
analysis demonstrates efficiency of ALCAM knockdown. Both ALCAM-Sh vectors, ALCAM Sh1 and ALCAM Sh2, showed effec-
tive suppression of the level of ALCAM protein, whereas the control vectors, ALCAM Scr1 and ALCAM Scr2, showed no inhibi-
tion. Cells were lysed 96 hours after infection. (B) ALCAM knockdown inhibited migration and invasion of two MM cell lines. (C) 
Inhibition of ALCAM with shRNA-mediated knockdown in MM cell lines suppressed anchorage-independent colony formation. 
Representative results of the NCI-H290 and Y-MESO-27 cell lines are shown (top) with higher magnifications of their represen-
tative colonies (bottom). The results of the triplicate experiments are presented. Columns, mean; bars, SD. ALCAM, Activated 
leukocyte cell-adhesion molecule; MM, malignant mesothelioma; shRNA, short hairpin RNA. *p < 0.05 vs. control.
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ALCAM in most MM cell lines and 55% surgical speci-
mens of MMs. ALCAM’s oncogenic properties served to 
promote migration and invasion in MM cells. Moreover, we 
demonstrated that the soluble isoform, sALCAM, impaired 
migration and invasion of MM cells in vitro and that sAL-
CAM-expressing virus infection prolonged the survival of 
MM cell-transplanted mice.
Elevated ALCAM expression was previously reported 
in melanoma and breast cancer cell lines,30,42 and immuno-
histochemical analysis of primary tumors revealed ALCAM 
expression in 36 to 57% of melanoma, pancreatic cancer, 
and bladder cancer.29,34,36 Thus, the frequency of elevated 
ALCAM expression in MM tumors seemed to be similar to 
or higher than that of other types of human malignancies. 
As for the possible mechanisms of ALCAM overexpression, 
our comparative genomic hybridization analysis did not 
detect gene amplification of 3q13 locus,43 which is the locus 
of the ALCAM gene. Meanwhile, a recent report by King et 
al42 indicated that nuclear factor kappa B (NF-B) binds to 
a consensus-binding motif in the human ALCAM promoter 
and enhances its promoter activity. In this regard, because 
NF-B was also shown to be induced in asbestos-exposed 
mesothelial cells and to play a critical role in the promotion 
and progression of MM cells,44,45 NF-B might be one of 
the underlying mechanisms of the ALCAM upregulation in 
MM cells.
We demonstrated that ALCAM promotes cell migra-
tion and invasion, but not cell proliferation, in MM cells. 
There are several possible mechanisms that the homophilic 
ALCAM cell-to-cell adhesion confers malignant phenotypes 
to cells. For instance, ALCAM cell adhesion was shown to 
contribute to the activation of matrix metalloproteinase-2 
(MMP-2), which is involved in tissue invasion, metastases, 
and angiogenesis.30,31 It was also indicated that short interfer-
ing RNA-mediated ALCAM knockdown inhibited activation 
of MMP-2 in melanoma and fibrosarcoma cells.30 Thus, these 
results suggested that the role of ALCAM might be to initi-
ate a signal to trigger MMP-2 activation. However, we did 
not confirm a clear MMP-2 inactivation in MM cells infected 
with the ALCAM-Sh1 expressing virus (data not shown). In 
addition, although we further performed phospho-kinase and 
phospho-receptor thyrosin kinase arrays to explore possible 
cellular mechanisms revealing how ALCAM confers malig-
nant phenotypes to MM cells, our knockdown experiments 
did not detect significant changes in phosphorylation status 
of all 88 proteins (data not shown).
FIGURE 4. Enhancement of cell migration and anchorage-independent growth of immortalized mesothelial cells, MeT-5A, 
with infection of ALCAM expressing virus. (A) Western blot analysis. Whole cell lysates of MeT-5A cells were obtained 96 
hours after infection of wild-type ALCAM or green fluorescent protein virus. (B) Immunocytochemical analysis. Positive 
signals of ALCAM were detected mainly at the cell-cell junction. (C) Cell migration and colony formation analysis of MeT-5A 
cells. Exogenous ALCAM enhanced migration and anchorage-independent cell growth of the MeT-5A cells. Columns, mean; 
bars, SD. ALCAM, Activated leukocyte cell-adhesion molecule; MM, malignant mesothelioma. *p < 0.05 versus GFP control.
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The extracellular domain of adhesion molecules can be 
released from cells to yield soluble cell-adhesion molecules, 
which are generated by proteolytic cleavage or alternative 
splicing.46–48 Regulatory roles of several soluble cell adhesion 
molecules have been shown to be involved in angiogenesis or 
tumor growth for intercellular adhesion molecule-1 49,50 and in 
cell migration for P-selectin.51 As for the soluble form sAL-
CAM, Kilsdonk et al31 showed that overexpressed sALCAM 
FIGURE 5. Purification of sALCAM 
and its inhibitory effects on MM cells. 
(A) Western blot analysis using anti-V5 
antibody. Secreted sALCAM in the con-
ditioned medium as well as in the whole 
cell lysates was confirmed. (B) Silver stain-
ing. Purity of synthesized sALCAM was 
confirmed with no obvious contaminated 
proteins. (C) Cell migration and invasion 
assays. In the presence of sALCAM protein 
at the indicated final concentration in the 
media, both migration and invasion abili-
ties of MM cells were significantly inhib-
ited. (D) Anchorage-independent colony 
formation assay. Anchorage-independent 
growth of NCI-H290 and Y-MESO-27 cell 
lines was suppressed with addition of sAL-
CAM. Columns, mean; bars, SD. sALCAM, 
soluble activated leukocyte cell-adhesion 
molecule; MM, malignant mesothelioma. 
*p < 0.05 vs. control.
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impaired the migration of melanoma cells and diminished lung 
metastases of melanoma cells in vivo. Thus, their results sug-
gested that sALCAM may also act as a tumor suppressor for 
the tumor cells with ALCAM expression. As we also showed 
the inhibitory effect of sALCAM on MM cells, we considered 
sALCAM to possibly have a therapeutic potential for MM.
ALCAM has also been shown to be a target molecule 
for immunotherapeutic modality against human cancers. For 
example, an internalizing single-chain antibody fragment 
directed to ALCAM, which was conjugated to immunolipo-
somal cytotoxic agents was shown to effectively target and kill 
ALCAM-expressing ovarian-cancer and prostate-cancer cells 
in vitro.52,53 Wiiger et al54 also demonstrated the potential role 
of a human recombinant anti-ALCAM antibody as a therapeu-
tic agent against colon and breast cancers. Thus, these newly 
developed immunotherapeutic agents might also be beneficial 
for MM treatment.
In conclusion, our study revealed that overexpression of 
ALCAM contributes positively to MM progression and that 
sALCAM effectively inhibits tumor progression. We consid-
ered that ALCAM might be a potential therapeutic target of 
MM. Further investigation about the detailed mechanisms 
of how cell migration, invasion. and anchorage-independent 
growth can be enhanced in MM cells by ALCAM is also 
needed to provide new insights into a more effective strategy 
to target the ALCAM expressed on MM cells.
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